Sigmoid announces major deal with Inncardio

Sigmoid Biotechnologies today announced an agreement with Inncardio for the co-development and licence of two novel formulations of established drugs.

Sigmoid announces major deal with Inncardio

Sigmoid Biotechnologies today announced an agreement with Inncardio for the co-development and licence of two novel formulations of established drugs.

The deal is anticipated to help achieve combined peak annual sales of $1bn (€760m).

Already a subscriber? Sign in

You have reached your article limit.

Subscribe to access all of the Irish Examiner.

Annual €130 €80

Best value

Monthly €12€6 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited